Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Merck and Moderna's Melanoma Breakthrough: Pembrolizumab and Neoantigen Vaccine Combo Shows Promise

Guavy AI Editorial Team
Instruments
MRK
Share

Merck and Moderna have announced positive phase 3 results for their adjuvant pembrolizumab (pembro) treatment combined with a personalized mRNA-based neoantigen vaccine in patients with melanoma.

This development was highlighted by Paolo Tarantino, who called it 'the future' of cancer treatment. The announcement comes ahead of the ESMO 2026 conference, where further details are expected to be presented.

More on Stocks

Stocks 1m ago

Amazon Faces Deadline for $2.5 Billion Prime Settlement Refunds

Stocks 1m ago

Amazon Discounts Golf Gear: Save Big on Rangefinders, Polos, and Travel Bags

Stocks 6m ago

US Stocks Eye Volatile Start to Monday Amid Rising Interest Rates

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy